Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer
Open Access
- 7 October 2026
- journal article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5879-5890
Abstract
The application of antibody-drug conjugate (ADC) therapies in advanced bladder cancers may be improved through non-invasive molecular imaging and therapy with targeted radiation. Enfortumab and Sacituzumab, the antibody components for the ADCs PADCEV (Nectin-4 targeting) and TRODELVY (TROP2 targeting), were developed as ImmunoPET and radioimmunotherapeutic modalities in a HT1376 xenograft model of advanced bladder cancer. Both immuno-PET agents displayed distinct tumor uptake in vivo, with Sacituzumab showing higher accumulation (% ID/g) compared to Enfortumab, reflecting the higher TROP2 expression in this tumor model over Nectin-4. Further, both [177Lu]Lu-DOTA-Enfortumab and [177Lu]Lu-DOTA-Sacituzumab were effective in reducing the growth of tumors in vivo. The repurposing of well-validated ADC antibodies as theranostic radiopharmaceuticals is a promising approach for alternative or adjuvant therapies.Keywords
Funding Information
- Australian Research Council (ARC) (IH220100017)
- Telix Pharmaceuticals Limited
This publication has 40 references indexed in Scilit:
- Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinomaInternational Journal of Clinical Oncology, 2026
- Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trialAnnals of Oncology, 2025
- Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trialAnnals of Oncology, 2025
- 1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)Annals of Oncology, 2024
- On the shoulder of ADC: The development of 124I-IMMU-132, an iodine-124-labelled Trop-2-targeting molecular probe for micro-PET imagingBiomedicine & Pharmacotherapy, 2024
- Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder CancerEuropean Urology, 2024
- An iodine‑labelled Antibody–drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinomaInternational Journal of Pharmaceutics, 2023
- TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsEuropean Urology Oncology, 2022
- Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus MonkeysMolecular Imaging and Biology, 2016
- Production of 177Lu for Targeted Radionuclide Therapy: Available OptionsNuclear Medicine and Molecular Imaging, 2015